VTRS 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

VTRS ▼ -10.52% at T+20d

LONG call ✗ call lost -10.52% · α vs SPY -13.66% · entry $17.39 → $15.56

Next anchor: T+60d in 7w

Last close $16.48 (close Jun 12) · -5.23% from $17.39 entry

Entry anchored
May 7, 2026
via day open

T+1d

-1.27%

call -1.27% · α -2.10%

$17.17

settled 5w ago

T+5d

-0.12%

call -0.12% · α -1.62%

$17.37

settled 5w ago

T+20d

-10.52%

call -10.52% · α -13.66%

$15.56

settled 10d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Viatris reported Q1 2026 adjusted EPS of $0.59, 18% above consensus of $0.50, and revenue of $3.52B, 5% above consensus of $3.36B. Results were driven by strong growth in Greater China and brands, with adjusted EBITDA up 10% operationally. The company reaffirmed its 2026 guidance, signaling confidence in its turnaround and cost-savings plan.

Key Financial Metrics

Guidance

$14,450M - $14,950M

maintained

Free Cash Flow

$348.4M

Gross Margin

32.9%

Actionable Insight

The strong Q1 beat and reaffirmed guidance reinforce the narrative of operational improvement and cost savings from the enterprise-wide strategic review. Traders should watch upcoming PDUFA dates (MR-141 for presbyopia in October, low-dose estrogen patch in July) and the March 2026 Investor Event for long-term targets.

Key Facts

Q1 2026 total revenues of $3.517B, up 8% reported (3% operational) YoY
Adjusted EPS of $0.59 vs consensus $0.50 (18% beat); GAAP EPS $0.15
Adjusted EBITDA of $1.05B, up 14% reported (10% operational) YoY
Reaffirmed 2026 guidance: revenue $14.45-14.95B, adjusted EBITDA $4.15-4.45B, adjusted EPS $2.33-2.47
Greater China net sales up 22% reported (18% operational)
Fire at Nashik facility caused $71.9M write-off in Q1; expects to resume operations in April 2026

Financial Impact

Adjusted EPS beat by 18% ($0.59 vs $0.50); revenue beat by 5% ($3.517B vs $3.36B); guidance reaffirmed

revenueepsadjusted_ebitda

Risk Factors

Restructuring and fire-related costs could weigh on GAAP profitability
Generic competition and pricing pressure in developed markets
Execution risk on $700-850M restructuring program

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

67% bullish (18 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001792044-26-000025
Document: vtrs-20260507.htm	0001792044-26-000025
Document: 0001792044-26-000025-index-headers.html	0001792044-26-000025
Document: 0001792044-26-000025-index.html	0001792044-26-000025
Document: 0001792044-26-000025.txt	0001792044-26-000025
8-K Data (Synthetic)	0001792044-26-000025

4 reports for VTRS

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for VTRS — sortable, filterable
	Type				Now
May 13, 2026 4w ago	Court Ruling BULLISH ★ 7/10	$17.37 $16.17	▼ −6.91%	▼ −5.75%	$16.48 (−5.12%)
May 7, 2026 5w ago	8-K BULLISH ★ 7/10	$17.39 $17.37	▼ −0.12%	▼ −1.62%	$16.48 (−5.23%)
May 4, 2026 5w ago	8-K NEUTRAL ★ 3/10	$15.52 $17.17	▲ +10.63%	▲ +8.65%	$16.48 (+6.19%)
Feb 26, 2026 15w ago	8-K MIXED ★ 7/10	$15.12 $14.41	▼ −4.72%	▼ −3.59%	$16.48 (+8.99%)

US Market Status

Market Closed — Opens in 4h 32m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access